USE OF NATRIURETIC PEPTIDE RECEPTOR ANTAGONISTS TO TREAT OCULAR, OTIC AND NASAL EDEMETOUS CONDITIONS
Methods and compositions to treat edematous ocular, otic and nasal conditions are described.
1 . A method for treating an ocular edematous disorder, said method comprising administering a composition comprising a therapeutically effective amount of a non-peptide or stabilized peptide natriuretic peptide (ANP/BNP/CNP) receptor antagonist.
2 . The method of claim 1 , wherein the ocular edematous disorder is selected from the group consisting of corneal, conjunctival edema, retinal edema, and retinal detachment.
3 . The method of claim 1 , wherein the natriuretic peptide receptor antagonist is a peptide or non-peptide ANP/BNP/CNP analog or mimetic that exhibits antagonist activity at type-A and/or type-B natriuretic peptide receptors.
4 . The method of claim 3 , wherein the natriuretic peptide receptor antagonist is selected from the group consisting of HS-142-1, isatin, [Asu-7,23′]b-ANP-(7-28)], anantin, 3G12, and analogs thereof.
5 . The method of claim 4 , wherein the natriuretic peptide receptor antagonist is isatin.
6 . The method of claim 4 , wherein the natriuretic peptide receptor antagonist is HS-142-1.
7 . The method of claim 4 , wherein the natriuretic peptide receptor antagonist is an analog or derivative of isatin or HS-142-1.
8 . The method of claim 1 , wherein the amount of the natriuretic peptide receptor antagonist in the composition is from 0.01% to 2% by weight.
9 . The method of claim 1 , wherein the concentration of the natriuretic peptide receptor antagonist is from about 0.01 μM to about 50 μM.
10 . A method for treating an otic edematous disorder, said method comprising administering a composition comprising a therapeutically effective amount of a non-peptide or stabilized peptide natriuretic peptide receptor antagonist.
11 . The method of claim 10 , wherein the natriuretic peptide receptor antagonist is a peptide or non-peptide ANP/BNP/CNP analog or mimetic that exhibits antagonist activity at type-A and/or type-B natriuretic peptide receptors.
12 . The method of claim 11 , wherein the natriuretic peptide receptor antagonist is selected from the group consisting of HS-142-1, isatin, [Asu-7,23′]b-ANP-(7-28)], anantin, 3G12, and analogs thereof.
13 . The method of claim 12 , wherein the natriuretic peptide receptor antagonist is isatin.
14 . The method of claim 12 , wherein the natriuretic peptide receptor antagonist is HS-142-1.
15 . The method of claim 10 , wherein the amount of natriuretic peptide receptor antagonist in the composition is from 0.01% to 2% by weight.
16 . The method of claim 10 , wherein the concentration of natriuretic peptide receptor antagonist receptor in the composition is from about 0.01 μM to about 50 μM.
17 . A method for treating a nasal edematous disorder, said method comprising administering a composition comprising a therapeutically effective amount of a non-peptide or stabilized peptide natriuretic peptide receptor antagonist.
18 . The method of claim 17 , wherein the natriuretic peptide receptor antagonist is a peptide or non-peptide ANP/BNP/CNP analog or mimetic that exhibits antagonist activity at type-A and/or type-B natriuretic peptide receptors.
19 . The method of claim 18 , wherein the natriuretic peptide receptor antagonist is selected from the group consisting of HS-142-1, isatin, [Asu-7,23′]b-ANP-(7-28)], anantin, 3G12, and analogs thereof.
20 . The method of claim 19 , wherein the natriuretic peptide receptor antagonist is isatin.
21 . The method of claim 19 , wherein the natriuretic peptide receptor antagonist is HS-142-1.
22 . The method of claim 17 , wherein the amount of natriuretic peptide receptor antagonist in the composition is from 0.01% to 2% by weight.
23 . The method of claim 17 , wherein the concentrations of natriuretic peptide receptor antagonist in the composition is from about 0.01 μM to about 50 μM.